These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32890261)

  • 21. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.
    Grigorian-Shamagian L; Edel K; Esteve-Pastor MA; Aceña Á; Silva C; Delgado-Silva J; Ntaios G; Demerouti E; Brotons C
    Front Cardiovasc Med; 2021; 8():663361. PubMed ID: 34504874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
    Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
    PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polypill treatments for cardiovascular diseases.
    Webster R; Rodgers A
    Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.
    López-Jaramillo P; Barbosa E; Molina DI; Sanchez R; Diaz M; Camacho PA; Lanas F; Pasquel M; Accini JL; Ponte-Negretti CI; Alcocer L; Cobos L; Wyss F; Sebba-Barroso W; Coca A; Zanchetti A;
    J Hypertens; 2019 Jun; 37(6):1126-1147. PubMed ID: 30882601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.
    Webster R; Bullen C; Patel A; Selak V; Stepien S; Thom S; Rodgers A
    Int J Cardiol; 2017 Dec; 249():443-447. PubMed ID: 28986058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
    Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
    BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
    Sanz G; Fuster V
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polypill Variants (Quarter Pill Trials).
    Teo K; Yusuf S
    Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
    Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.